Investigational drugs in phase II clinical trials for the treatment of neuroblastoma

References

• Santana VM, Furman WL, Billups CA, et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol. 2005;23:4039–4047.
   PubMed Web of Science ®Google Scholar
• Rubie H, Chisholm J, Defachelles AS, et al. Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Societe Francaise des Cancers de l’Enfant and United Kingdom Children Cancer Study Group-New Agents Group study. J Clin Oncol. 2006;24(33):5259–5264.
   PubMed Web of Science ®Google Scholar
• Garaventa A, Luksch R, Biasotti S, et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer. 2003;98:2488–2494.
   PubMed Web of Science ®Google Scholar
• Amoroso L, Erminio G, Makin G, et al. Topotecan-vincristine-doxorubicin in stage 4 high risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC - a SIOPEN Study. Cancer Res Treat. 2017 Mar 21.
   PubMedGoogle Scholar
• Kushner BH, Kramer K, Modak S, et al. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol. 2006;24(33):5271–5276.
   PubMed Web of Science ®Google Scholar
• Bagatell R, London WB, Wagner LM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children’s Oncology Group Study. J Clin Oncol. 2011;29(2):208–213.
   PubMed Web of Science ®Google Scholar
• Di Giannatale A, Dias-Gastellier N, Devos A, et al. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma Study. Eur J Cancer. 2014;50:170–177.
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Modak S, et al. High-dose carboplatin–irinotecan–temozolomide: treatment option for neuroblastoma resistant to topotecan. Pediatr Blood Cancer. 2011;56:403–408.
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Modak S, et al. High-dose cyclophosphamide– irinotecan–vincristine for primary refractory neuroblastoma. Eur J Cancer. 2011;47:84–89.
   PubMed Web of Science ®Google Scholar
• London WB, Frantz CN, Campbell LA, et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children’s Oncology Group study. J Clin Oncol. 2010;28:3808–3815.
   PubMed Web of Science ®Google Scholar
• Simon T, Laängler A, Harnischmacher U, et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high risk neuroblastoma. Results of a phase-II trial. J Cancer Res Clin Oncol. 2007;133:653–661.
   PubMed Web of Science ®Google Scholar
• Mody R, Naranjo A, Van Ryn C, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017 May 23;pii:S1470-2045(17)30355-8.
   Google Scholar
• Shusterman S, London WB, Gillies SD, et al. Antitumor activity of Hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children’s Oncology Group (COG) phase II study. J Clin Oncol. 2010 Nov 20;28(33):4969–4975.
   PubMed Web of Science ®Google Scholar
• Modak S, Kushner BH, Basu E, et al. Combination of bevacizumab, irinotecan and temozolomide for refractory or relapsed neuroblastoma: results of a phase II study. Pediatr Blood Cancer. 2017;64:e26448.
   Web of Science ®Google Scholar
• Furman WL, McGregor LM, McCarville MB, et al. A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. Invest New Drugs. 2012;30(4):1660–1670.
   PubMed Web of Science ®Google Scholar
• Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients: a Pediatric Oncology Group Study. Clin Can Res. 2001;7(1):32–37.
   PubMed Web of Science ®Google Scholar
• Vassal G, Doz F, Frappaz D, et al. A phase I study of irinotecan as a 3- week schedule in children with refractory or recurrent solid tumors. J Clin Oncol. 2003;21(20):3844–3852.
   PubMed Web of Science ®Google Scholar
• Bomgaars LR, Bernstein M, Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. 2007;25(29):4622–4627.
   PubMed Web of Science ®Google Scholar
• Vassal G, Giammarile F, Brooks M, et al. A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Societe Francaise d’Oncologie Pediatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). Eur J Cancer. 2008;44(16):2453–2460.
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Modak S, et al. Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma. Cancer. 2005;103(4):858–862.
   PubMed Web of Science ®Google Scholar
• Blaney SM, Needle MN, Gillespie A, et al. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children’s Cancer Group Study. Clin Cancer Res. 1998;4:357–360.
   PubMed Web of Science ®Google Scholar
• Daw NC, Santana VM, Iacono LC, et al. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol. 2004;22:829–837.
   PubMed Web of Science ®Google Scholar
• Laängler A, Christaras A, Abshagen K, et al. Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood – a phase-II-study. Klin Padiatr. 2002;214:153–156.
   PubMed Web of Science ®Google Scholar
• Park JR, Scott JR, Stewart CF, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children’s Oncology Group Study. J Clin Oncol. 2011;29(33):4351–4357.
   PubMed Web of Science ®Google Scholar
• Pourquier P, Pilon AA, Kohlhagen G, et al. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J Biol Chem. 1997;272(42):26441–26447.
   PubMed Web of Science ®Google Scholar
• Moreno L, Laidler J, Moroz V, et al. A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma: BEACON-neuroblastoma, an European innovative therapies for children with cancer (ITCC)— International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial [abstract]. J Clin Oncol. 2015;33(Suppl).
   PubMed Web of Science ®Google Scholar
• Kushner BH, Modak S, Kramer K, et al. 5-Day/5-drug myeloablative outpatient regimen for resistant neuroblastoma. Bone Marrow Transplant. 2013;48(5):642–645.
   PubMed Web of Science ®Google Scholar
• Bagatell R, Norris R, Ingle AM, et al. Phase 1 trial of temsirolimusin combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children’s Oncology Group Study. Pediatr Blood Cancer. 2014;61(5):833–839.
   PubMed Web of Science ®Google Scholar
• DuBois SG, Marachelian A, Fox E, et al. Phase I study of the aurora a kinase inhibitor alisertib in combination with irinotecan and temozolomidefor patients with relapsed or refractory neuroblastoma: a NANT (New Approaches to Neuroblastoma Therapy) trial. J Clin Oncol. 2016;34(12):1368–1375.
   PubMed Web of Science ®Google Scholar
• Beaty O 3rd, Berg S, Blaney S, et al. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children’s Oncology Group study. Pediatr Blood Cancer. 2010 Sep;55(3):440–445.
   PubMed Web of Science ®Google Scholar
• Geoerger B, Chisholm J, Le Deley M-C, et al. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: an innovative therapy for children with Cancer European Consortium Study. Eur J Cancer. 2011;47:230–238.
   PubMed Web of Science ®Google Scholar
• Warwick AB, Malempati S, Krailo M, et al. Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children’s Oncology Group Study. Pediatr Blood Cancer. 2013 Feb;60(2):237–241.
   PubMed Web of Science ®Google Scholar
• Minard-Colin V, Ichante JL, Nguyen L, et al. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma–a report from the Société Française des Cancers et leucémies de l’Enfant et de l’adolescent (SFCE). Eur J Cancer. 2012 Oct;48(15):2409–2416.
   PubMed Web of Science ®Google Scholar
• Zhang L, Marrano P, Kumar S, et al. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors. Clin Cancer Res. 2013;19(21):5972–5983.
   PubMed Web of Science ®Google Scholar
• Fouladi M, Park JR, Stewart F, et al. Pediatric Phase I trial and pharmacokinetic study of vorinostat: a children’s Oncology Group Phase I Consortium Report. J Clin Oncol. 2010;28:3623–3629.
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–1334.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves first therapy for high-risk neuroblastoma. [ cited 2015 Nov 16]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm437460.htm
   Google Scholar
• Unituxin (dinutuximab) injection [product information]. Silver Spring (MD): United Therapeutics Corp; 2015.
   Google Scholar
• Cheung N-KV, Cheung IY, Kramer K, et al. Key role for myeloid cells: phase II results of anti-GD2 antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. Int J Cancer. 2014;135:2199–2205.
   PubMed Web of Science ®Google Scholar
• Cheung N-KV, Cheung IY, Kushner BH, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012;30:3264–3270.
   PubMed Web of Science ®Google Scholar
• Kushner BH, Ostrovnaya I, Cheung IY, et al. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study. OncoImmunology. 2015 Jul;4(7).
   PubMed Web of Science ®Google Scholar
• Ribatti D, Surico G, Vacca A, et al. Angiogenesis extent and expressionof matrix metalloproteinase-2 and −9 correlate with progression in human neuroblastoma. Life Sci. 2001;68(10):1161–1168.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Marimpietri D, Pastorino F, et al. Angiogenesis in neuroblastoma. Ann N Y Acad Sci. 2004 Dec;1028:133–142. Review.
   PubMed Web of Science ®Google Scholar
• Peddinti R, Zeine R, Luca D, et al. Prominent microvascular proliferationin clinically aggressive neuroblastoma. Clin Can Res. 2007;13(12):3499–3506.
   PubMed Web of Science ®Google Scholar
• Komuro H, Kaneko S, Kaneko M, et al. Expression of angiogenic factors and tumor progression in human neuroblastoma. J Cancer Res Clin Oncol. 2001;127(12):739–743.
   PubMed Web of Science ®Google Scholar
• Skoldenberg EG, Larsson A, Jakobson A, et al. The angiogenic growth factors HGF and VEGF in serum and plasma from neuroblastoma patients. Anticancer Res. 2009;29(8):3311–3319.
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O’Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593–4599.
   PubMed Web of Science ®Google Scholar
• Braghiroli MI, Sabbaga J, Hoff PM. Bevacizumab: overview of the literature. Expert Rev Anticancer Ther. 2012;12(5):567–580.
   PubMed Web of Science ®Google Scholar
• Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. 2008;26(3):399–405.
   PubMed Web of Science ®Google Scholar
• Furman WL, Navid F, Daw NC, et al. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol. 2009;27(27):4599–4604.
   PubMed Web of Science ®Google Scholar
• Donfrancesco A, De Ioris MA, McDowell HP, et al. Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response. Pediatr Blood Cancer. 2010 Jan;54(1):55–61.
   PubMed Web of Science ®Google Scholar
• Weigel B, Malempati S, Reid JM, et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2014 Mar;61(3):452–456.
   PubMed Web of Science ®Google Scholar
• Gilheeney SW, Lyden DC, Sgouros S, et al. A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies. Pediatr Blood Cancer. 2007 Sep;49(3):261–265.
   PubMed Web of Science ®Google Scholar
• Glade Bender JL, Lee A, Reid JM, et al. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children’s oncology group phase I consortium report. J Clin Oncol. 2013 Aug 20;31(24):3034–3043. Epub 2013 Jul.
   PubMed Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4:335–348.
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22.
   PubMed Web of Science ®Google Scholar
• Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol. 2009;36:S3–S17.
   PubMedGoogle Scholar
• Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turnsin the road to cancer therapy. Clin Cancer Res. 2007;13:3109–3114.
   PubMed Web of Science ®Google Scholar
• Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006;66:5549–5554.
   PubMed Web of Science ®Google Scholar
• Marimpietri D, Brignole C, Nico B, et al. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin Cancer Res. 2007 Jul 1;13(13):3977–3988.
   PubMed Web of Science ®Google Scholar
• Marimpietri D, Nico B, Vacca A, et al. Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene. 2005 Oct 13;24(45):6785–6795.
   PubMed Web of Science ®Google Scholar
• Geoerger B, Kerr K, Tang CB, et al. Antitumor activity of the rapamycin analog CCI-779 inhuman primitive neuroectodermal tumor/medulloblastoma models as single agent and incombination chemotherapy. Cancer Res. 2001;61:1527–1532.
   PubMed Web of Science ®Google Scholar
• Johnsen JI, Segerstrom L, Orrego A, et al. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene. 2008;27:2910–2922.
   PubMed Web of Science ®Google Scholar
• Geoerger B, Kieran MW, Grupp S, et al. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer. 2012 Jan;48(2):253–262.
   PubMed Web of Science ®Google Scholar
• Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008;455:971–974.
   PubMed Web of Science ®Google Scholar
• George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455:975–978.
   PubMed Web of Science ®Google Scholar
• Janoueix-Lerosey I, Lequin D, Brugires L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008;455:967–970.
   PubMed Web of Science ®Google Scholar
• Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930–935.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advancednon-small cell lung cancer. Drugs. 2013;73(18):2031–2051.
   PubMed Web of Science ®Google Scholar
• Mosse YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol. 2013 May;14(6):472–480.
   PubMed Web of Science ®Google Scholar
• Balis FM, Thompson PA, Mosse YP, et al. First dose and steady state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium. Cancer Chemother Pharmacol. 2017;79:181–187.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Mahadevan D, Cebula E, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014;32:44–50.
   PubMed Web of Science ®Google Scholar
• Mossé YP, Lipsitz E, Fox E, et al. Pediatric Phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of aurora kinase a: a children’s oncology group Phase I Consortium Study. Clin Cancer Res. 2012 Nov 1;18(21):6058–6064.
   PubMed Web of Science ®Google Scholar
• Bond M, Bernstein ML, Pappo A, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children’s Oncology Group study. Pediatr Blood Cancer. 2008 Feb;50(2):254–258.
   PubMed Web of Science ®Google Scholar
• Te Kronnie G, Timeus F, Rinaldi A, et al. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition. Int J Mol Med. 2004;14:373–382.
   PubMed Web of Science ®Google Scholar
• Vitali R, Cesi V, Nicotra MR, et al. c-Kit is preferentially expressed in MYCNamplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571. Int J Cancer. 2003;106:147–152.
   PubMed Web of Science ®Google Scholar
• Meco D, Riccardi A, Servidei T, et al. Antitumor activity of imatinib mesylate in neuroblastoma xenografts. Cancer Lett. 2005;228:211–219.
   PubMed Web of Science ®Google Scholar
• Calafiore L, Amoroso L, Della Casa Alberighi O, et al. Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma. Ann Oncol. 2013;24:1406–1413.
   PubMed Web of Science ®Google Scholar
• Adamson PC, Matthay KK, O’Brien M, et al. A Phase 2 trial of all-trans-retinoic acid in combination with interferon-a2A in children with recurrent neuroblastoma or wilms tumor: a pediatric oncology branch, NCI and Children’s Oncology Group Study. Pediatr Blood Cancer. 2007;49:661–665.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med. 1999;341:1165–1173.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children’s Oncology Group Study. J Clin Oncol. 2009;27:1007–1013.
   PubMed Web of Science ®Google Scholar
• Reynolds CP, Wang Y, Melton LJ, et al. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med Pediatr Oncol. 2000;35:597–602.
   PubMedGoogle Scholar
• Ponzoni M, Bocca P, Chiesa V, et al. Differential effects of N-(4-hydroxyphenyl) retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res. 1995 Feb 15;55(4):853–861.
   PubMed Web of Science ®Google Scholar
• Maurer BJ, Metelitsa LS, Seeger RC, et al. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines. J Natl Cancer Inst. 1999;91:1138–1146.
   PubMed Web of Science ®Google Scholar
• Villablanca JC, London WB, Naranjo A, et al. Phase II study of oral capsular 4-hydroxyphenylretinamide (4- HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children’s Oncology Group. Clin Cancer Res. 2011 Nov 1;17(21):6858–6866.
   PubMed Web of Science ®Google Scholar
• Maurer BJ, Kalous O, Yesair DW, et al. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex. Clin Cancer Res. 2007;13:3079–3086.
   PubMed Web of Science ®Google Scholar
• Kang MH, Marachelian A, Villablanca JG, et al. Fenretinide (4-HPR) orally formulated in Lym-X-Sorb(LXS) lipid matrix or as an intravenous emulsion increased 4-HPR systemic exposure in patients with recurrent or resistant neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) consortium trial [abstract]. Proc ANR. 2010;123. (abstract # OR57).
   Google Scholar
• Hogarty MD, Norris MD, Davis K, et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res. 2008;68(23):9735–9745.
   PubMed Web of Science ®Google Scholar
• Lutz W, Stohr M, Schurmann J, et al. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene. 1996;13(4):803–812.
   PubMed Web of Science ®Google Scholar
• Ben-Yosef T, Yanuka O, Halle D, et al. Involvement of Myc targets in c-myc and N-myc induced human tumors. Oncogene. 1998;17(2):165–171.
   PubMed Web of Science ®Google Scholar
• Lu X, Pearson A, Lunec J. The MYCN oncoprotein as a drug development target. Cancer Lett. 2003;197(1–2):125–130.
   PubMed Web of Science ®Google Scholar
• Saulnier Sholler GL, Gerner EW, Bergendahl G, et al. A Phase I trial of DFMO targeting polyamine addiction in patients with relapsed/refractory neuroblastoma. PLoS One. 2015 May 27;10(5):e0127246.
   PubMed Web of Science ®Google Scholar